Latest Breaking News On - Kintor pharma - Page 1 : vimarsana.com

Acne Vulgaris Market to Register Sustainable Growth by 2034, Examines DelveInsight | Key Companies - Dermata Therapeutics, AstraZeneca, Novartis Pharmaceuticals, UCB Pharma, Incyte Corporation

/PRNewswire/ -- DelveInsight's Acne Vulgaris Market Insights report includes a comprehensive understanding of current treatment practices, acne vulgaris...

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

Kintor Pharma Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China

Propulsion of Acne Vulgaris Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Acne Vulgaris Pipeline constitutes 22+ key companies continuously working towards developing 22+ Acne Vulgaris Pipeline treatment therapies,

Kintor Pharma Announces 2023 Interim Results and -2-

Kintor Pharma Announces 2023 Interim Results and Recent Business Highlights

Kintor Pharmaceutical : Pharma Announces 2023 Interim Results and Recent Business Highlights -Today at 09:01 am

Suzhou, August 28, 2023 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2023...

Kintor Pharmaceutical : Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China -Today at 04:54 am

Suzhou, August 22, 2023 - Kintor Pharmaceutical Limited , a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company...

Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China

/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and...

Kintor Pharma Announces Completion of First Patient Enrollment in Long-term Safety Phase III Trial of KX-826 for Treatment of AGA

/PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and...